<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00955630</url>
  </required_header>
  <id_info>
    <org_study_id>FVF 4147S</org_study_id>
    <nct_id>NCT00955630</nct_id>
  </id_info>
  <brief_title>Intravitreal Ranibizumab for the Treatment of Choroidal Neovascularization in Ocular Histoplasmosis Syndrome</brief_title>
  <acronym>IVL for OHS</acronym>
  <official_title>Intravitreal Ranibizumab for the Treatment of Choroidal Neovascularization in Ocular Histoplasmosis Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Retina Associates of Kentucky</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Retina Associates of Kentucky</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and effectiveness of intravitreal
      ranibizumab (Lucentis) in patients with fluid and blood leakage in their eyes due to ocular
      histoplasmosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be evaluated monthly for one year.

      Participants will be assigned to one of two groups:

      Group A will receive 3 monthly injections of ranibizumab followed by an as needed injection
      throughout the remainder of the study Group B will receive injections of ranibizumab on an as
      needed basis throughout the study

      You cannot take part in this study if:

        1. You are pregnant or intending to become pregnant in the next 12 months or are nursing an
           infant

        2. You are under the age of 18
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2009</start_date>
  <primary_completion_date type="Anticipated">August 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>incidence and severity of ocular adverse events as identified by eye examination</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>incidence and severity of other adverse events as identified by physical examination, subject reporting, and changes in vital signs</measure>
    <time_frame>12 mos</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>mean change in visual acuity</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mean change in central foveal thickness and total macular volume as obtained by ocular coherence tomography</measure>
    <time_frame>6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in fluorescein angiographic outcomes</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mean number of injections</measure>
    <time_frame>12 mos</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Ocular Histoplasmosis Syndrome</condition>
  <arm_group>
    <arm_group_label>Monthly injections</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3 monthly injections of ranibizumab followed by prn injections</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PRN injections</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>injections of ranibizumab on a prn basis from the start of the study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ranibizumab</intervention_name>
    <description>3 monthly injections of ranibizumab followed by prn injections for the remainder of the study</description>
    <arm_group_label>Monthly injections</arm_group_label>
    <other_name>Lucentis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ranibizumab</intervention_name>
    <description>prn injections of ranibizumab throughout the study</description>
    <arm_group_label>PRN injections</arm_group_label>
    <other_name>Lucentis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 18 or over

          -  active choroidal neovascularization secondary to ocular histoplasmosis

          -  Visual acuity between 20/25 and 20/400

        Exclusion Criteria:

          -  pregnancy or intent to become pregnant within the next 12 months

          -  nursing an infant

          -  premenopausal women not using contraception

          -  prior treatment with subfoveal thermal laser

          -  allergy to sodium fluorescein simultaneous participation in another investigation or
             trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Kitchens, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Retina Associates of Kentucky</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Diana Holcomb, COA</last_name>
    <phone>859-263-3900</phone>
    <phone_ext>145</phone_ext>
    <email>dholcomb@retinaky.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wanda Heath, BS, COT, CCRC</last_name>
    <phone>859-263-3900</phone>
    <phone_ext>106</phone_ext>
    <email>wheath@retinaky.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Retina Associates of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40509</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>John Kitchens, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tom Stone, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>William J Wood, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rick D Isernhagen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 7, 2009</study_first_submitted>
  <study_first_submitted_qc>August 7, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2009</study_first_posted>
  <last_update_submitted>August 7, 2009</last_update_submitted>
  <last_update_submitted_qc>August 7, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 10, 2009</last_update_posted>
  <responsible_party>
    <name_title>Dr. John Kitchens, Md/Principal Investigator</name_title>
    <organization>Retina Associates of Kentucky</organization>
  </responsible_party>
  <keyword>Histoplasmosis</keyword>
  <keyword>Lucentis</keyword>
  <keyword>Ranibizumab</keyword>
  <keyword>OHS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Neovascularization, Pathologic</mesh_term>
    <mesh_term>Choroidal Neovascularization</mesh_term>
    <mesh_term>Histoplasmosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>May 31, 2013</submitted>
    <returned>July 31, 2013</returned>
    <submitted>August 7, 2013</submitted>
    <returned>October 11, 2013</returned>
    <submitted>June 13, 2014</submitted>
    <submission_canceled>Unknown</submission_canceled>
    <submitted>September 23, 2014</submitted>
    <returned>September 24, 2014</returned>
    <submitted>June 9, 2015</submitted>
    <returned>June 11, 2015</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

